about
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.Erythropoietin on cycling performance - Authors' reply.Cerebrovascular events during nilotinib treatment.Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial.A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced Growth Hormone Secretion In A First-in-human Clinical TrialRepeatability and predictive value of lactate threshold concepts in endurance sportsA novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine productsPhase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumorsA phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumorsImmunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
P50
Q38082728-23683C0B-418F-47D0-9DA8-0A610AAC0F8DQ41195857-0681E021-01AB-4A70-8D8A-FA772E531B60Q47897979-2185593A-057F-4661-88EF-CC9225FEB59AQ50048405-660FB721-4FA0-4169-9581-ACF59B80E0AEQ53923184-04F331BE-2E7E-4020-B08C-3BEE4DB90153Q54365439-5E8B93F2-0504-4CD2-8E1D-2C3A62B2F93FQ55060177-EE2C91FC-A2DD-4252-90B5-155CA34608DFQ58114792-07243DC0-D4A9-4BBA-B90D-A024211564EDQ59807607-2A402DF4-A29F-42AD-9067-E4A31557923DQ79329846-418F29C6-C942-4D1B-81C0-4E5884D0D5C4Q85945062-24FFB68B-D8C9-4FA7-BFC0-3DF2DD4332FFQ86965718-CBDB01B8-8DAB-4F73-B1A2-167EBD143775Q90233076-0335829E-E97C-49EA-B9EC-38C6D90DDDC3Q92883136-990C78A2-BC53-456D-8B37-E2CEBDC48B34
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Frederik E Stuurman
@ast
Frederik E Stuurman
@en
Frederik E Stuurman
@es
Frederik E Stuurman
@nl
type
label
Frederik E Stuurman
@ast
Frederik E Stuurman
@en
Frederik E Stuurman
@es
Frederik E Stuurman
@nl
prefLabel
Frederik E Stuurman
@ast
Frederik E Stuurman
@en
Frederik E Stuurman
@es
Frederik E Stuurman
@nl
P106
P108
P21
P31
P496
0000-0002-0013-8355